Tiova Inhaler
$ 201,00 – $ 680,00Price range: $ 201,00 through $ 680,00
Tizacare
$ 40,00 – $ 285,00Price range: $ 40,00 through $ 285,00
Tiova Rotacap
$ 45,00 – $ 86,00Price range: $ 45,00 through $ 86,00
Tiova Rotacap is an effective long-acting bronchodilator designed for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). It contains Tiotropium, which helps to keep the airways open by relaxing the muscles surrounding the bronchial tubes. This medication is primarily used to manage and prevent symptoms such as wheezing and shortness of breath associated with emphysema and chronic bronchitis. By improving lung function over time, it significantly enhances daily respiratory comfort and physical activity levels. Consistent use of these inhalation capsules provides reliable, 24-hour support for individuals seeking better control over their respiratory health.
Active substance: Tiotropium
SKU:
Tiova Rotacap
Category: Asthma
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Tiova Rotacap belongs to a class of medications known as long-acting muscarinic antagonists (LAMAs), containing the active active substance tiotropium bromide. It is prescribed as a long-term maintenance treatment for adult patients diagnosed with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema.
In accordance with United States federal regulations, this inhalation medication is dispensed by prescription only (Rx) under medical supervision. It is designed solely for oral inhalation via a specialized dry powder inhaler device and must never be swallowed orally or used as a rescue remedy for sudden, acute breathing distress.
Clinical Overview and Usage
Key Information Overview
| Parameter | Specification |
|---|---|
| Active ingredient (INN) | Tiotropium bromide |
| Therapeutic class | Anticholinergic / Long-acting muscarinic antagonist (LAMA) |
| Dosage form | Dry powder capsule for inhalation |
| Route of administration | Oral inhalation (via dry powder inhaler) |
| Primary purpose | Maintenance treatment of airway obstruction in COPD |
| Prescription status | Prescription only (Rx) |
How the drug works
The active component, tiotropium bromide, operates as a long-acting, competitive antagonist at muscarinic acetylcholine receptors within the human respiratory tract. By selectively binding to M3 muscarinic receptors located on smooth muscle cells surrounding the bronchial passages, tiotropium inhibits the bronchoconstrictive actions of endogenous acetylcholine. This pharmacological blockade produces prolonged relaxation of the airway smooth musculature, thereby increasing pulmonary airflow and reducing hyperinflation. The intrinsic dissociation half-life of tiotropium from the M3 receptor is significantly longer than from M2 receptors, establishing its functional selectivity and supporting a sustained 24-hour bronchodilatory response following a single daily dose.
What it’s used for
Tiova Rotacap is indicated strictly for the long-term, once-daily maintenance therapy of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. It is targeted at reducing exacerbations and improving overall pulmonary function parameters, such as forced expiratory volume in one second (FEV1). This product is not indicated for the initial treatment of acute episodes of bronchospasm (rescue therapy) or for asthma, unless explicitly evaluated and prescribed under specific FDA-approved combined management protocols. Usage in pediatric populations has not been established as safe or effective.
Dosing Schedule
Administration of Tiova Rotacap must strictly adhere to the dosing instructions provided by the prescribing healthcare professional. The standard adult maintenance dose is the inhalation of the contents of one capsule once daily at the same time each day using a designated dry powder inhaler. The gelatin capsules are engineered exclusively for insertion into the inhaler chamber to puncture and release the dry powder into the airstream; they must never be ingested orally. Patients should be instructed on proper inhalation technique: exhaling fully away from the device, placing the mouthpiece tightly between the lips, and inhaling deeply and steadily through the mouth. Maximum therapeutic benefit depends on regular, daily administration.
How it’s absorbed and eliminated
Following oral inhalation, absolute bioavailability of tiotropium bromide dry powder is estimated at approximately 19 to 33 percent, indicating that the fraction reaching the systemic circulation is primarily absorbed via the pulmonary tissues. Peak plasma concentration (Cmax) occurs within 5 to 7 minutes post-inhalation. Tiotropium exhibits a plasma protein binding rate of approximately 72 percent and a volume of distribution of 32 L/kg. Metabolism is minimal, mediated primarily in non-enzymatic pathways and via cytochrome P450 enzymes CYP2D6 and CYP3A4. Excretion occurs predominantly unchanged through urine (approximately 74 percent of the systemically absorbed dose), while unabsorbed drug is eliminated in the feces. The effective terminal elimination half-life ranges from 5 to 6 days in COPD patients.
Safety Profile and Frequently Asked Questions
Compatibility with other medicines
Concomitant administration of Tiova Rotacap with other anticholinergic-containing medications (such as ipratropium, aclidinium, or umeclidinium) is not recommended, as co-administration may intensify systemic anticholinergic adverse effects without providing additional therapeutic benefit. Co-administration with inhaled corticosteroids, oral corticosteroids, methylxanthines (such as theophylline), or short-acting beta2-agonists does not generally alter the pharmacokinetic profile of tiotropium. However, caution is advised when using drugs eliminated via active renal secretion (e.g., cimetidine), as potential interactions mediated through organic cation transporters cannot be entirely ruled out in patients with compromised renal function.
Adverse Reactions
The safety evaluation of tiotropium bromide reflects its systemic and localized anticholinergic property profile. The most frequently reported adverse reaction reported in clinical investigations is dry mouth (xerostomia), which generally presents as mild and often resolves spontaneously during continued therapy. Additional observed side effects include:
- Gastrointestinal: Constipation, gastroesophageal reflux, abdominal discomfort, localized oral candidiasis.
- Respiratory: Cough, pharyngitis, dysphonia, epistaxis, and rhinitis.
- Cardiovascular: Tachycardia, palpitations, and supraventricular arrhythmias.
- Renal and Urinary: Urinary retention, dysuria, and urinary tract infections, particularly in elderly male patients.
- Nervous System: Dizziness, headache, and taste perversion (dysgeusia).
Important precautions
Tiova Rotacap should be prescribed with heightened caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction, as anticholinergic agents can precipitate acute angle-closure glaucoma or acute urinary retention. Patients with moderate-to-severe renal impairment (creatinine clearance less than or equal to 50 mL/min) must be monitored closely, because decreased clearance can lead to increased plasma drug concentrations. As with other inhalation therapies, immediate hypersensitivity reactions (including anaphylaxis, angioedema, rash, and urticaria) or paradoxical bronchospasm may occur; if paradoxical bronchospasm occurs, treatment must be discontinued immediately and alternative therapy instituted.
Food and alcohol interactions
Because Tiova Rotacap is delivered directly to the pulmonary tract via inhalation, systemic absorption is not affected by food intake. There are no direct pharmacokinetic interactions with alcohol; however, concurrent consumption of excessive alcohol may exacerbate nervous system adverse effects such as dizziness or unsteadiness. Patients are advised to maintain consistent hydration to manage mild anticholinergic dry mouth.
Red flags
Immediate emergency medical assistance should be sought if any of the following severe adverse manifestations develop during treatment:
- Signs of immediate hypersensitivity: swelling of the face, lips, tongue, or throat, accompanied by severe difficulty swallowing or breathing.
- Sudden onset of severe paradoxical bronchospasm (increased wheezing or acute chest tightness immediately after dose inhalation).
- Signs of acute angle-closure glaucoma: severe eye pain or discomfort, blurred vision, visual halos around lights, accompanied by red eyes.
- Inability to pass urine, painful urination, or marked decrease in urinary output.
If you skip a dose
If a dose of Tiova Rotacap is missed, it should be administered as soon as remembered on the same day. However, if it is near the time for the next scheduled dose, the missed dose should be skipped entirely, and the normal once-daily regimen resumed. Patients must never inhale two doses on the same day to make up for a missed capsule.
Storage and expiration
Tiova Rotacap capsules must be stored in their original blister packaging to protect the dry powder from ambient moisture and light. Store at controlled room temperature, ideally between 68°F to 77°F (20°C to 25°C), with excursions permitted between 59°F and 86°F (15°C and 30°C). Do not expose capsules to extreme heat or high humidity environments (such as bathrooms). Capsules should only be removed from the foil packaging immediately before insertion into the inhalation device. Expiry dates printed on the packaging must be strictly observed; expired product should be disposed of in accordance with local drug disposal protocols.
Common Questions
What should I do if a Rotacap capsule is accidentally swallowed orally instead of inhaled?
If a capsule is swallowed orally, the systemic bioavailability of tiotropium bromide is extremely low, meaning systemic toxicity is unlikely. However, the patient will not receive the therapeutic pulmonary benefit for that day’s dose. Medical advice should be sought from a healthcare provider or poison control center if accidental oral ingestion occurs, and patients should be reinstructed on proper device administration.
Can Tiova Rotacap be used to treat an acute attack of shortness of breath?
No. Tiova Rotacap is a long-acting maintenance bronchodilator with a gradual onset of action and is not formulated for rapid reversal of acute bronchospasm. Patients must always carry a short-acting, rapid-onset inhaled beta2-agonist (such as albuterol) to manage sudden, acute breathing difficulty.
Is it safe to operate heavy machinery or drive after administering tiotropium inhalation powder?
Tiotropium bromide generally does not impair cognitive function; however, central nervous system side effects such as dizziness or visual disturbances (e.g., blurred vision) have been reported in some patients. Individuals experiencing these effects should refrain from driving or operating machinery until symptoms fully resolve.
How does severe kidney impairment affect the clearance of tiotropium bromide?
Because tiotropium is primarily cleared unchanged through renal excretion, patients with moderate-to-severe renal impairment (creatinine clearance ≤ 50 mL/min) demonstrate higher plasma concentrations and longer elimination half-lives. Prescribers evaluate the benefit-risk profile carefully in these individuals and monitor for anticholinergic side effects.
Are there any specific guidelines for using Tiova Rotacap during pregnancy?
There are no adequate and well-controlled studies evaluating tiotropium bromide in pregnant women. Animal reproduction studies have not demonstrated direct developmental toxicity at clinically relevant doses, but the drug should only be used during pregnancy if the potential maternal benefit clearly justifies the potential risk to the fetus. Prescribers should be consulted before starting or continuing therapy during pregnancy or lactation.
This text is for informational purposes only and does not constitute individual medical advice. In accordance with FDA requirements.
Additional information
| Dosage |
18 mcg |
|---|---|
| Package |
30 caps ,60 caps ,90 caps |
| Ενεργός Ουσία |
Related products
Advair Diskus
$ 72,00 – $ 527,00Price range: $ 72,00 through $ 527,00
More Details
This product has multiple variants. The options may be chosen on the product page
Asthalin Inhaler
$ 50,00 – $ 215,00Price range: $ 50,00 through $ 215,00
Active substance: Salbutamol
More Details
This product has multiple variants. The options may be chosen on the product page
Atrovent
$ 22,00 – $ 65,00Price range: $ 22,00 through $ 65,00
Active substance: Ipratropium bromide
More Details
This product has multiple variants. The options may be chosen on the product page
Claritin
$ 43,00 – $ 143,00Price range: $ 43,00 through $ 143,00
Active substance: Loratadine
More Details
This product has multiple variants. The options may be chosen on the product page
Combimist L Inhaler
$ 60,00 – $ 81,00Price range: $ 60,00 through $ 81,00
Active substance: ipratropium, Levosalbutamol
More Details
This product has multiple variants. The options may be chosen on the product page
Foracort Inhaler
$ 47,00 – $ 345,00Price range: $ 47,00 through $ 345,00
Active substance: Budesonide, Formoterol
More Details
This product has multiple variants. The options may be chosen on the product page
Haridra
$ 48,00
Active substance: Haridra
More Details
This product has multiple variants. The options may be chosen on the product page
Montair
$ 19,00 – $ 45,00Price range: $ 19,00 through $ 45,00
Active substance: Montelukast
More Details
This product has multiple variants. The options may be chosen on the product page
